Pharmaceutical Market Europe
Author: Phil Taylor featuring Dr. Chitra Lele, Sciformix Corporation
As might be expected, smaller CROs insist there is room for all, particularly where they have a strong focus in a specific therapeutic area, geography or the type of service provided.
“While we are sure that the trend of preferred partnerships with large CROs is here to stay, we believe that there is a distinct role that niche vendors will continue to play and be an important part of the provider ecosystem,” says Chitra Lele, Chief Scientific Officer at India-based CRO Sciformix.
Niche regional providers are also more likely to work with the local affiliates of large pharma companies and with mid to small size pharma companies, according to Lele, who says there are also increasingly opportunities for smaller players to work with larger CROs.
“CROs have to continuously invest in human and other resources to ensure delivery as per client expectations, and this can add to their overheads and impact the cost benefit of the deals,” she notes, adding: “they sometimes partner with niche providers who are able to provide the right skills at the right price and assume part of the responsibility of ensuring quality and timeliness of projects.”